Revive Therapeutics Partners With UCSF To Study Bucillamine For Severe COVID-19

Revive Therapeutics (CSE: RVV) this morning had a major announcement, in that it has entered into a sponsored research agreement with the University of California, San Francisco. The arrangement will see Bucillamine explored as a potential treatment for severe COVID-19.

The research conducted on Bucillamine is to be conducted in the lab of Dr John Fahy, a notable name as the lab is responsible for the report entitled, “Binding of SARS-CoV-2 spike protein to ACE2 is disabled by thiol-based drugs; evidence from in vitro SARS-CoV-2 infection studies.” The report serves as the basis for which Bucillamine was initially studied as a potential treatment for COVID-19.

Revive is currently undergoing a phase 3 study examining the use of Bucillamine in the treatment of mild-moderate COVID-19. The news today effectively expands ongoing research to include severe instances as well, although initial studies into the application for severe cases is currently pre-clinical.

“We are excited to expand the use of Bucillamine as a potential treatment for severe COVID-19 with our research agreement with UCSF and Dr. Fahy as Principal Investigator.  Revive is focused on proving Bucillamine’s clinical utility for all forms of COVID-19. Evaluating Bucillamine for severe COVID-19 along with our dedication in completing our ongoing Phase 3 clinical study for mild-to-moderate COVID-19, which has grown from 14 clinical sites to now 26 participating sites in 10 U.S. states, will position Bucillamine as a potential oral treatment option for mild-moderate to severe COVID-19.”

Michael Frank, CEO of Revive Therapeutics

Dr Fahy is a Professor of Medicine in the Division of Pulmonary and Critical Care Medicine and the Department of Medicine at the University of California, San Francisco. He also serves as a director of the severe asthma clinic at UCSF, along with the Airway Clinical Research Center.

Revive Therapeutics last traded at $0.48 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

2026 Could Be Gold’s Biggest Year Yet!? | Ryan King – Equinox Gold

Gold Is Screaming Higher While Currencies Burn | Simon Ridgway – Rackla Metals

We Have the Highest-Grade Antimony Deposit in North America!? | Jim Atkinson -Antimony Resources

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Denmark to Begin Offering Covid-19 ‘Vaccine Passport’ for Travelers in Early 2021

As the coronavirus pandemic continues to spiral out of control and decimate air travel around...

Thursday, January 14, 2021, 04:01:00 PM

Households Amassed a Pile of Excess Cash in 2020. Will it Fuel the Economic Recovery?

The economic restrictions imposed during the height of the second world war make today’s pandemic-induced...

Saturday, March 13, 2021, 11:45:00 AM

Empower Clinics Receives Repeat Order For 5,000 Test Kits

Empower Clinics (CSE: CBDT) this morning announced that it has received a notable purchase order...

Wednesday, April 14, 2021, 07:45:28 AM

Revive Selects Clinical Sites for FDA Phase 3 Clinical Trials

This morning Revive Therapeutics Ltd (CSE: RVV, OTV: RVVTF), announced they have selected five clinical...

Tuesday, September 29, 2020, 09:45:22 AM

#PfizerExposed: Did Pfizer Just Admit To “Engineering” Virus For COVID-19 Pill In Response To Project Veritas Video?

After a video of a top Pfizer (NYSE: PFE) executive relaying that the biotech firm...

Saturday, January 28, 2023, 10:59:30 AM